Lifestyle
- Regular moderate exercise
- Stress management techniques
- Adequate sleep
Interleukin-6 · Interleukin 6
IL-6 quantifies the concentration of interleukin-6, a cytokine involved in inflammation and immune response.
Levels can vary based on age, sex, and health status. Fasting and time of day may influence results.
Interleukin-6 (IL-6) is a cytokine involved in the regulation of immune responses, inflammation, and hematopoiesis. It is produced by various cell types, including leukocytes, adipocytes, and endothelial cells. IL-6 plays a critical role in the acute phase response, stimulating the production of acute-phase proteins like C-reactive protein (CRP) in the liver. Clinically, IL-6 is a significant biomarker for inflammatory conditions and cardiovascular diseases. Elevated IL-6 levels are associated with increased risk of atherosclerosis, cardiogenic shock, and other cardiovascular complications. It is also implicated in cancer progression, particularly in inflammation-induced malignancies like cholangiocarcinoma. In the context of athletic performance and biohacking, IL-6 is of interest due to its role in muscle repair and adaptation to exercise. However, chronic elevation may indicate overtraining or systemic inflammation, which can negatively impact performance and recovery. Researchers observed that IL-6 levels can be influenced by various factors, including stress, infection, and exercise. Time-of-day and fasting status may also affect measurements, necessitating standardization in testing protocols to ensure accurate interpretation.
Klinische Bedeutung
Elevated IL-6 levels indicate systemic inflammation and are associated with cardiovascular disease, infection, and certain cancers. Reduced levels are less commonly discussed but may reflect immunosuppression.
Progressively rising IL-6 levels suggest worsening inflammation or disease progression. Re-test every 4 weeks if outside the optimal range.
Decreasing IL-6 levels may indicate improvement in inflammatory status or effective treatment.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting new supplements, especially if on medication.
IL-6 levels may vary throughout the day; morning tests are recommended for consistency.
Testing Frequency
Annually for general health monitoring, more frequently if managing chronic conditions.
Correlated with
Current research suggests that the perioperative kinetics of IL-6 in cardiac surgical patients remain insufficiently understood, with unclear influencing factors and clinical implications. Researchers have not yet established optimal reference ranges for IL-6 in various conditions, particularly in cardiogenic shock and cholangiocarcinoma. Additionally, clinical questions remain unanswered regarding the efficacy of IL-6-targeted therapies and the specific mechanisms linking IL-6 to poor prognostic outcomes across different inflammatory diseases.
1,245
Total Citations
16
Human/RCT
3.8
Avg. Influence
2025
Latest
This review examined the role of interleukin-6 (IL-6) in cardiovascular disease and its potential as a biomarker for vascular risk. Researchers found that IL-6 signaling is linked to atherogenesis and suggested that inhibiting IL-6 could provide vascular protection. The study also highlighted the development of ziltivekimab, an IL-6 ligand inhibitor, for use in high-risk cardiovascular patients.
This study explored the significance of C-reactive protein (CRP) as a marker of inflammation, which is influenced by interleukin-6 (IL-6). Researchers found that CRP is widely used in clinical laboratories for diagnosing inflammatory conditions and has gained attention as a biomarker for COVID-19 severity. The study emphasized the importance of CRP in managing systemic inflammatory diseases.
This review highlighted the significance of interleukin-6 (IL-6) in Castleman disease, particularly its role in the hyperfunction of IL-6 in affected lymph nodes. Researchers found that treatments targeting IL-6, such as tocilizumab, improve symptoms in patients with multicentric Castleman disease. The study emphasizes IL-6's central role in the disease's pathogenesis.
This study demonstrated a new biosensor for detecting interleukin-6 (IL-6), a biomarker associated with inflammation and severe COVID-19. Researchers achieved a detection range from picomolar to nanomolar concentrations and confirmed the sensor's selectivity against other cytokines. The biosensor could improve IL-6 detection in clinical settings.
Researchers conducted a systematic review on interleukin-6 (IL-6) as a prognostic biomarker in traumatic brain injury (TBI). They found that elevated IL-6 levels were associated with poorer clinical outcomes, although results varied across studies.
This review summarized the role of interleukin-6 (IL-6) in neurodegenerative disorders, noting its involvement in neuroinflammation. Researchers found that high levels of IL-6 are frequently associated with these disorders, suggesting its potential as a biomarker for disease progression and prognosis. The study emphasizes the need for further research on IL-6's signaling pathways.
This study investigated the relationship between interleukin-6 (IL-6) levels and clinical staging in amyotrophic lateral sclerosis (ALS) patients. Researchers found that while IL-6 levels were elevated in ALS patients, variability in levels was noted, and a correlation was observed between IL-6 and respiratory dysfunction. The study highlights the influence of age and respiratory factors on IL-6 levels.
This article explored the role of interleukin-6 (IL-6) in ischemic stroke. Researchers found that IL-6 is a significant inflammatory mediator during the acute phase of a stroke and may serve as a reliable prognostic factor for patient outcomes. The study highlighted the need for further research on IL-6's impact on stroke severity.
Researchers measured interleukin-6 (IL-6) levels in cerebrospinal fluid from meningitis patients. They found that IL-6 was elevated in both aseptic and bacterial meningitis, indicating its potential as a rapid diagnostic marker. This study suggests that cytokine measurement could enhance meningitis diagnosis.
This study investigated the relationship between lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6) in the context of atherosclerotic cardiovascular disease (ASCVD). Researchers found that IL-6 receptor inhibitors can lower Lp(a) levels and may have dual effects on inflammation and apolipoprotein synthesis, suggesting potential benefits in ASCVD prevention. The study calls for more trials to clarify these interactions.
9
Total Trials
1,503
Total Enrolled
Federal University of Minas Gerais
66
2026
Inflammatory Biomarkers: Serum interleukin-6 (IL-6) concentratio
Zhongshan Hospital Xiamen University
50
2026
Trans-Thrombus Interleukin-6 Gradient
Universidad Autonoma de Nuevo Leon
50
2025
Change in interleukin-6 (IL-6) levels
Utah State University
36
2023
Inflammatory cytokine biomarker (IL-6) concentrations in plasma samples
Ministry of Health, Saudi Arabia
60
2022
measurement of interleukin-6 at exhaled condensate in covid-19, postcovid-19 ,healthy subjects
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
140
2021
DAS28-C-reactive Protein (CRP) change
Kirby Institute
0
2021
Change from baseline in IL-6 level at week 48
University of Ulm
1,000
2014
Interleukin-6 (IL-6) plasma concentration
Insel Gruppe AG, University Hospital Bern
101
2012
Inflammatory response, as determined by whole blood analysis of inflammatory biomarkers (IL-6, CRP, TNF alpha, CD62L)
Research publications about IL-6 over time
7totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer